PMAM
KYMR icon

Penn Mutual Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Penn Mutual Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,327
Closed -$1.18M – 92
2021
Q1 		$1.18M Buy
+30,327
New +$1.83M 1.33% 18

Other funds holding KYMR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DIC
Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Penn Mutual Asset Management's KYMR Position: Q2 2021 in Review

Penn Mutual Asset Management sold out of Kymera Therapeutics (KYMR) in Q2 2021, closing a stake of 30,327 shares — an estimated $1.18M sold.

Penn Mutual Asset Management first reported a position in KYMR in Q1 2021 and held it in 1 quarter. The position peaked at $1.18M in Q1 2021. 110 funds tracked by Wall St. Rank hold KYMR as of Q2 2021.

  • Penn Mutual Asset Management reported no remaining Kymera Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Penn Mutual Asset Management sold 30,327 Kymera Therapeutics shares in Q2 2021, an estimated $1.18M.
  • Penn Mutual Asset Management first reported a position in Kymera Therapeutics in Q1 2021 and held it in 1 quarter.
  • Penn Mutual Asset Management's Kymera Therapeutics position peaked at $1.18M in Q1 2021.
  • 110 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2021.

Based on Penn Mutual Asset Management's 13F filing for Q2 2021, filed 26 Aug 2021.